// App-Quantinova.ai

TPS178 : A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).

Researchers

Presenter

  • Charles S. Fuchs

Principal Investigators

  • Josep Tabernero

  • Salah-Eddin Al-Batran

  • Ian Chau

  • David H. Ilson

  • Eric Van Cutsem

  • Kohei Shitara

  • David Ferry

  • Michael Emig

  • Veerle Vanvoorden

  • Yanzhi Hsu

  • Yihuan Xu

  • Andreas Sashegyi

  • Mayukh Das

  • Manish A. Shah

Medical Centers

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Institut of Clinical Cancer Research - University Cancer Center Frankfurt, Frankfurt, Germany

  • The Royal Marsden Hospital, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University Hospital Gasthuisberg, Leuven, Belgium

  • Depertment of Surgical Oncology, National Cancer Center Hospital East, Chiba, Japan

  • Eli Lilly and Company, Bridgewater, NJ

  • Lilly Deutschland GmbH, Bad Homburg, Germany

  • Eli Lilly and Company, Brussels, Belgium

  • Eli Lilly and Company, Indianapolis, IN

  • Weill Cornell Medical College, New York, NY

Locations

  • United States

  • Spain

  • Germany

  • United Kingdom

  • Belgium

  • Japan

Companies

  • Eli Lilly and Compan

  • Lilly Deutschland Gm

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Capecitabine

  • Ramucirumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02314117

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved